글로벌 용혈성 빈혈 시장 – 2031년까지의 산업 동향 및 예측

용혈성 빈혈 시장 분석 및 규모

시장은 용혈성 빈혈의 유병률 증가, 질병에 대한 인식 증가, 진단 기술의 발전과 같은 요인에 의해 향후 몇 년 동안 꾸준한 성장을 보일 것으로 예상됩니다. 시장은 또한 선진국과 개발도상국 모두에서 증가하는 의료비 지출로 인해 혜택을 볼 가능성이 높으며, 이를 통해 진단 및 치료에 대한 접근성이 향상될 것입니다. 또한 용혈성 빈혈을 관리하기 위한 새로운 치료법과 약물을 개발하면 시장 성장이 더욱 촉진될 것으로 예상됩니다. 

글로벌 용혈성 빈혈 시장 규모는 2023년에 3억 4,347만 달러로 평가되었으며, 2031년까지 5억 2,313만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 5.40%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화       

Market Definition

Hemolytic anemia is a medical condition characterized by prematurely destroying red blood cells (RBCs) in the body. This can occur either within the blood vessels (intravascular hemolysis) or in organs such as the spleen or liver (extravascular hemolysis). Hemolysis, or the breakdown of red blood cells, can lead to various symptoms, including fatigue, jaundice (yellowing of the skin and eyes), pale skin, dark urine, and shortness of breath.      

Hemolytic Anemia Market Dynamics

Drivers

• Increasing Prevalence of Hemolytic Anemia

The rising prevalence of hemolytic anemia globally can be attributed to various factors, including genetic predisposition, autoimmune disorders, and infections. Genetic factors play a crucial role in developing hemolytic anemia, with certain genetic mutations predisposing individuals to the condition. In addition, autoimmune disorders, where the immune system mistakenly attacks healthy red blood cells, can lead to hemolytic anemia. Infections, particularly those that affect the red blood cells directly or trigger an immune response that targets these cells, are also linked to the development of hemolytic anemia. As the prevalence of these risk factors continues to rise, the overall burden of hemolytic anemia is expected to increase, driving the demand for diagnostic and treatment options in the market.     

• Advancements in Diagnostic Technologies   

Molecular diagnostics, such as polymerase chain reaction (PCR) and next-generation sequencing (NGS), have revolutionized the field of hemolytic anemia diagnosis by enabling the detection of genetic mutations associated with the condition. These methods enable the timely and precise identification of hemolytic anemia, which is crucial for efficiently managing and treating the condition. Biomarker testing is another advancement that has improved the diagnosis of hemolytic anemia by identifying specific markers in the blood that indicate the presence of the condition. These advancements have improved diagnostic accuracy and enabled healthcare professionals to tailor treatment plans to individual patients, leading to better outcomes and driving market growth.          

Opportunities

• Growing Awareness and Healthcare Infrastructure     

As awareness levels rise, more cases of hemolytic anemia are likely to be diagnosed early, leading to increased demand for diagnostic tests and treatments. In addition, expanding healthcare infrastructure, particularly in developing regions, is expected to drive market growth. Improved access to healthcare facilities and services in these regions will enable more patients to seek diagnosis and treatment for hemolytic anemia, expanding the market size. The growing awareness about hemolytic anemia among healthcare professionals and patients presents a significant market opportunity.  

• Rising Healthcare Expenditure       

As healthcare expenditure rises, more resources are allocated towards improving healthcare infrastructure, increasing access to healthcare services, and enhancing diagnostic and treatment capabilities. This is expected to result in more hemolytic anemia cases being identified and managed, while also stimulating innovation in diagnostic and therapeutic technologies. Moreover, as healthcare systems become more advanced and efficient, the overall quality of care for hemolytic anemia patients is expected to improve, further driving market growth. 

Restraints/Challenges

• Side Effects Associated with Treatment   

Immunosuppressive therapies can be effective in managing the condition, but they often come with risks of adverse effects, including increased susceptibility to infections and other immune-related complications. These side effects can limit the use of these therapies and impact market growth. These side effects associated with certain treatments for hemolytic anemia, such as immunosuppressive therapies, present a significant challenge.  

• Limited Availability of Effective Therapies    

Insufficient access to effective treatments impacts patient outcomes and spurs the search for novel and innovative treatment alternatives. Patients in different regions may face difficulties in accessing appropriate therapies, leading to suboptimal management of their condition. The lack of effective treatments also creates a gap in the market and poses a significant challenge to market growth.

This hemolytic anemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hemolytic anemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Hemolytic Anemia Market Scope

The market is segmented on the basis of treatment type, route of administration, diagnosis, end-users, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Blood Transfusions
• Medicines
• Corticosteroids
• Others
• Plasmapheresis
• Surgery
• Blood and Marrow Stem Cell Transplants
• Others

Route of Administration

• Oral
• Parenteral
• Others

Diagnosis

• Blood Tests
• Biopsy
• Urine Tests
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Hemolytic Anemia Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, treatment type, route of administration, diagnosis, end-users, and distribution channel as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America.

North America is expected to dominate the market due to its well-established healthcare infrastructure. Moreover, the increasing emphasis of major key players on innovative technology and the continuous introduction and approval of new products further contribute to regional growth.

Asia-Pacific is expected to witness significant growth during the forecast period due to its large population and increasing healthcare expenditure, along with the availability of effective treatment options at comparatively lower prices than those offered by Western manufacturers.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

이 시장은 또한 자본 장비에 대한 의료 지출의 모든 국가별 성장, 용혈성 빈혈 시장을 위한 다양한 종류의 제품의 설치 기반, 수명선 곡선을 사용한 기술의 영향, 의료 규제 시나리오의 변화 및 시장에 미치는 영향에 대한 자세한 시장 분석을 제공합니다. 이 데이터는 2016-2021년의 과거 기간에 대해 제공됩니다.

경쟁 환경 및 용혈성 빈혈 시장 점유율 분석

시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 글로벌 입지, 생산 현장 및 시설, 생산 용량, 회사의 강점과 약점, 제품 출시, 제품 폭과 범위, 애플리케이션 우세입니다. 위에 제공된 데이터 포인트는 시장과 관련된 회사의 초점에만 관련이 있습니다.

시장에서 활동하는 주요 기업은 다음과 같습니다.

• F. 호프만-라 로슈 유한회사(스위스)
• 마일런 NV(미국)
• Teva Pharmaceutical Industries Ltd.(아일랜드)
• 사노피(프랑스)
• 파이저 주식회사(미국)
• GlaxoSmithKline plc (영국)
• 노바티스 AG(스위스)
• AbbVie Inc.(미국)
• Fresenius SE & Co. KGaA(독일)
• 루팡(인도)
• ViforPharma Ltd. (스위스)
• AMAG Pharmaceuticals (미국)
• Akebia Therapeutics, INC. (미국)
• CHO-A Pharmaceutical CO., LTD. (한국)
• 오리온 코퍼레이션(핀란드)
• Pharmacosmos A/S(덴마크)
• 쉴드 테라퓨틱스(영국)
• Advanz Pharmaceutical(영국)
• Alkem Labs(인도)
• 지두스 카딜라(인도)
• 히크마 제약(영국)

SKU-53424